Shared on07 Aug 25Fair value Increased 0.80%
With the consensus analyst price target unchanged at $69.44, Halozyme Therapeutics saw a modest improvement in valuation as its future P/E declined, signaling slightly enhanced earnings expectations. What's in the News Halozyme raised 2025 earnings guidance, expecting total revenue of $1,275–$1,355 million (26–33% growth) and royalty revenue of $825–$860 million (44–51% growth) over 2024.
Shared on30 Apr 25Fair value Decreased 0.17%
AnalystConsensusTarget made no meaningful changes to valuation assumptions.
Shared on23 Apr 25Fair value Increased 0.56%
AnalystConsensusTarget made no meaningful changes to valuation assumptions.
Shared on17 Apr 25
AnalystConsensusTarget made no meaningful changes to valuation assumptions.
Shared on09 Apr 25
AnalystConsensusTarget made no meaningful changes to valuation assumptions.
Shared on02 Apr 25Fair value Increased 9.38%
AnalystConsensusTarget made no meaningful changes to valuation assumptions.
Shared on26 Mar 25
AnalystConsensusTarget made no meaningful changes to valuation assumptions.
Shared on19 Mar 25
AnalystConsensusTarget made no meaningful changes to valuation assumptions.
Shared on10 Mar 25Fair value Increased 0.16%
AnalystConsensusTarget has decreased future PE multiple from 10.7x to 9.4x.